Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation.

Christian D Rolfo Russell W Madison Lincoln W Pasquina Derek W Brown Yanmei Huang Jason D Hughes Ryon P Graf Geoffrey R Oxnard Hatim Husain

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Patients with lung cancer with negative LBx and ctDNA TF ≥1% are unlikely to have a driver detected on confirmatory tissue testing; such informative negative results may benefit instead from prompt treatment initiation. Conversely, negative LBx with ctDNA TF <1% will commonly have a driver identified by follow-up tissue testing and should be prioritized for reflex testing.

Keyphrases

circulating tumor
gene expression
genome wide
replacement therapy
smoking cessation